Neurally mediated cardiac effects of forskolin in conscious dogs

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 271, Issue 4 40-4, 1996, Pages

  Iwase, Mitsunori ^g   Ishikawa, Yoshihiro ^g   Shen, You Tang ^a   Shannon, Richard P ^b   Sato, Naoki ^g   Ganguly, Pallab K ^c   Eki, Toshiko ^d   Vatner, Dorothy E ^e   Vatner, Stephen F ^f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Health Science Center   (Canada)

^d NIPPON KAYAKU CO LTD   (Japan)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g NONE

Author keywords

chronotropic effect; inotropic effect; neural effects; synergism

Indexed keywords

6 (3 DIMETHYLAMINOPROPIONYL)FORSKOLIN; ADENYLATE CYCLASE; ATROPINE METHYL BROMIDE; BETA ADRENERGIC RECEPTOR; FORSKOLIN; ISOPRENALINE; MORPHINE SULFATE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CHRONOTROPISM; CONTROLLED STUDY; DOG; DRUG DISTRIBUTION; DRUG POTENTIATION; ENZYME ACTIVATION; GANGLION BLOCK; HEART DENERVATION; HEART FAILURE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBER MEMBRANE; HEART MUSCLE ISCHEMIA; HEART RATE; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RAT; SYMPATHETIC TONE;

EID: 0029861706     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1996.271.4.h1473     Document Type: Article

References (32)

1. Baumann, G., S. Felix, U. Sattelberger, and G. Klein. Cardiovascular effects of forskolin (HL 362) in patients with idiopathic congestive cardiomyopathy - a comparative study with dobutamine and sodium nitroprusside. J. Cardiovasc. Pharmacol. 16: 93-100, 1990.
2. Bender, J. L., and E. J. Neer. Properties of the adenylate cyclase catalytic unit from caudate nucleus. J. Biol. Chem. 258: 2432-2439, 1983.
3. Bristow, M. R., R. Ginsburg, A. Strosberg, W. Montgomery, and W. Minobe. Pharmacology and inotropic potential of forskolin in the human heart. J. Clin. Invest. 74: 212-223, 1984.
4. Cryer, P. E. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system N Engl. J. Med. 303: 436-444, 1980.
5. Daly, J. W. Forskolin, adenylate cyclase, and cell physiology: an overview. Adv. Cyclic Nucleotide Res. 17: 81-89, 1984.
6. DuPont, E., C. E. Jones, R. A. Luedecke, and E. E. Smith. Chronic ventricular sympathetectomy: effect on myocardial perfusion after ligation of the circumflex coronary artery in dogs. Circ. Shock 6: 323-331, 1979.
7. Hosono, M., T. Takahira, A. Fujita, R. Fujihara, O. Ishizuka, T. Tatee, and K. Nakamura. Cardiovascular and adenylate cyclase stimulant properties of NKH 477, a novel water-soluble forskolin derivative. J. Cardiovasc. Pharmacol. 19: 625-634, 1992.
8. Ishikawa, Y., S. Sorota, K. Kiuchi, R. P. Shannon, K. Komamura, S. Katsushika, S. F. Vatner, D. E. Vatner, and C. J. Homey. Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. J. Clin. Invest. 93: 2224-2229, 1994.
9. Katz, I. R., D. Smith, and M. H. Makman. Forskolin stimulates the conversion of tyrosine to dopamine in catecholaminergic neural tissue. Brain Res. 264: 173-177, 1983.
10. Kiuchi, K., R. P. Shannon, K. Komamura, D. J. Cohen, C. Bianchi, C. J. Homey, S. F. Vatner, and D. E. Vatner. Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. J. Clin. Invest. 91: 907-914, 1994.
11. Kiuchi, K., Y.-T. Shen, S. F. Vatner, and D. E. Vatner. Mechanisms mediating responsiveness to β-adrenergic stimulation after coronary reperfusion in conscious dogs. Am. J. Physiol. 267 (Heart Circ. Physiol. 36): H1578-H1588, 1994.
12. Krammer, W., J. Thormann, M. Kindler, and M. Schlepper. Effects of forskolin on left ventricular function in dilated cardiomyopathy. Arzneim. Forsch. 37: 364-367, 1987.
13. Kusachi, S., W. J. Bugni, and R. A. Olsson. Forskolin potentiates the coronary vasoactivity of adenosine in the open-chest dog. Circ. Res. 55: 116-119, 1984.
14. Lebedinsky, Y., S. T. Nordstrom, S. E. Aschoff, J. F. Kapples, G. J. O'Malley, R. W. Kosley, Jr., S. Fielding, and J. W. Hubbard. Cardiotonic and coronary vasodilator responses to milrinone, forskolin, and Analog P87-7692 in the anesthetized dog. J. Cardiovasc. Pharmacol. 19: 779-789, 1992.
15. Lindner, E., A. N. Dohadwalla, and B. K. Bhattacharya. Positive inotropic and blood pressure lowering activity of a diterpene derivative isolated from Coleus forskohli: forskolin. Arzneim. Forsch. 28: 284-289, 1978.
16. Metzger, H., and E. Lindner. The positive inotropic-acting forskolin, a potent adenylate cyclase activator. Arzneim. Forsch. 31: 1248-1250, 1981.
17. Motomiya, T., S. Hosoda, T. Katagiri, T. Takano, and H. Toshima. Acute effect of NKH477, a novel forskolin derivative in patients with acute heart failure: a multicenter placebo controlled double-blind trial (Abstract). Circulation 92: 1-332, 1995.
18. Peuler, J. D., and G. A. Johnson. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine, and dopamine. Life Sci. 21: 625-636, 1977.
19. Rajagopalan, R., A. V. Ghate, P. Subbarayan, W. Linz, and B. A. Sehoelkens. Cardiotonic activity of the water soluble forskolin derivative 8, 13-epoxy-6β-(piperidinoacetoxy)-1α,7β,9α-trihydroxy-labd- 14en-11-one. Arzneim. Forsch. 43: 313-319, 1993.
20. Salomon, Y., C. Londos, and M. Rodbell. A highly sensitive adenylate cyclase assay. Anal. Biochem. 58: 541-548, 1974.
21. Schlepper, M., J. Thormann, V. Mitrovic. Cardiovascular effects of forskolin and phosphodiesterase III inhibitors. Basic Res. Cardiol. 84, Suppl. 1: 197-212, 1989.
22. Seaman, K. B., and J. W. Daly. Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J. Cyclic. Nucleotide Res. 1: 201-224, 1981.
23. Seamon, K. B., and J. W. Daly. Forskolin, cyclic AMP and cellular physiology. Trends Pharmacol. Sci. 4: 120-123, 1983.
24. Seamon, K. B., and J. W. Daly. Forskolin: its biological and chemical properties. Adv. Cyclic Nucleotide Res. 20: 1-150, 1986.
25. Seamon, K. B., W. Padgett, and J. W. Daly. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells Proc. Natl. Acad. Sci. USA 78: 3363-3367, 1981.
26. Shen, Y.-T., D. R. Knight, S. F. Vatner, W. C. Randall, and J. X. Thomas, Jr. Responses to coronary artery occlusion in conscious dogs with selective cardiac denervation. Am. J. Physiol. 255 (Heart Circ. Physiol. 24): H525-H533, 1988.
27. Silverberg, A. B., S. D. Shah, M. W. Raymond, and P. E. Cryer. Norepinephrine: hormone and neurotransmitter in man. Am. J. Physiol. 234 (Endocrinol. Metab. Gastrointest. Physiol. 3): E252-E256, 1978.
28. Stengel, D., L. Guenet, M. Desmier, P. Insel, and J. Hanoune. Forskolin requires more than the catalytic unit to activate adenylate cyclase. Mol. Cell. Endocrinol. 28: 681-690, 1982
29. 0-Proc. Natl. Acad. Sci. USA. 85: 7013-7017, 1988.
30. Vatner, D. E., K. Kiuchi, W. T. Manders, and S. F. Vatner. Effects of coronary arterial reperfusion on β-adrenergic receptor-adenylyl cyclase coupling. Am. J. Physiol. 264 (Heart Circ. Pkysiol. 33): H196-H204, 1993.
31. Woodman, O. L., and S. F. Vatner. Cardiovascular responses to the stimulation of alpha-1 and alpha-2 adrenoceptors in the conscious dog. J. Pharmacol. Exp. Ther. 237: 86-91, 1986.
32. Young, M. A., T. H. Hintze, and S. F. Vatner. Correlation between cardiac performance and plasma catecholamine levels in conscious dogs. Am. J. Physiol. 248 (Heart Circ. Physiol 17). H82-H88, 1985.